Ghent University Academic Bibliography

Advanced

Phase 2 studies of immunochemotherapy +/- bortezomib (VC) in newly diagnosed non-germinal center B-cell-like (GCB) DLBCL: rapid prospective identification of non-GCB patients (PTS)

Fritz Offner UGent, B Ferhanoglu, JA Reeves, HS Eom, K Doner, J Raposo, IW Flinn, C Suh, NM Chowhan, S Prasad, et al. (2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.225-225
Please use this url to cite or link to this publication:
author
organization
year
type
conference (meetingAbstract)
publication status
published
subject
in
ANNALS OF ONCOLOGY
Ann. Oncol.
volume
22
issue
suppl. 4
pages
225 - 225
conference name
11th International conference on Malignant Lymphoma
conference location
Lugano, Switzerland
conference start
2011-06-15
conference end
2011-06-18
Web of Science type
Meeting Abstract
Web of Science id
000291996300448
JCR category
ONCOLOGY
JCR impact factor
6.425 (2011)
JCR rank
17/190 (2011)
JCR quartile
1 (2011)
ISSN
0923-7534
language
English
UGent publication?
yes
classification
C3
id
2119874
handle
http://hdl.handle.net/1854/LU-2119874
date created
2012-05-30 09:49:28
date last changed
2016-12-19 15:36:40
@inproceedings{2119874,
  author       = {Offner, Fritz and Ferhanoglu, B and Reeves, JA and Eom, HS and Doner, K and Raposo, J and Flinn, IW and Suh, C and Chowhan, NM and Prasad, S and Kussick, SJ and Mulligan, G and Rizo, A and Leonard, JP},
  booktitle    = {ANNALS OF ONCOLOGY},
  issn         = {0923-7534},
  language     = {eng},
  location     = {Lugano, Switzerland},
  number       = {suppl. 4},
  pages        = {225--225},
  title        = {Phase 2 studies of immunochemotherapy +/- bortezomib (VC) in newly diagnosed non-germinal center B-cell-like (GCB) DLBCL: rapid prospective identification of non-GCB patients (PTS)},
  volume       = {22},
  year         = {2011},
}

Chicago
Offner, Fritz, B Ferhanoglu, JA Reeves, HS Eom, K Doner, J Raposo, IW Flinn, et al. 2011. “Phase 2 Studies of Immunochemotherapy +/- Bortezomib (VC) in Newly Diagnosed Non-germinal Center B-cell-like (GCB) DLBCL: Rapid Prospective Identification of non-GCB Patients (PTS).” In Annals of Oncology, 22:225–225.
APA
Offner, F., Ferhanoglu, B., Reeves, J., Eom, H., Doner, K., Raposo, J., Flinn, I., et al. (2011). Phase 2 studies of immunochemotherapy +/- bortezomib (VC) in newly diagnosed non-germinal center B-cell-like (GCB) DLBCL: rapid prospective identification of non-GCB patients (PTS). ANNALS OF ONCOLOGY (Vol. 22, pp. 225–225). Presented at the 11th International conference on Malignant Lymphoma.
Vancouver
1.
Offner F, Ferhanoglu B, Reeves J, Eom H, Doner K, Raposo J, et al. Phase 2 studies of immunochemotherapy +/- bortezomib (VC) in newly diagnosed non-germinal center B-cell-like (GCB) DLBCL: rapid prospective identification of non-GCB patients (PTS). ANNALS OF ONCOLOGY. 2011. p. 225–225.
MLA
Offner, Fritz, B Ferhanoglu, JA Reeves, et al. “Phase 2 Studies of Immunochemotherapy +/- Bortezomib (VC) in Newly Diagnosed Non-germinal Center B-cell-like (GCB) DLBCL: Rapid Prospective Identification of non-GCB Patients (PTS).” Annals of Oncology. Vol. 22. 2011. 225–225. Print.